Mineralys Therapeutics, Inc. MLYS Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -31%+5.9pp | -36.9%+5.2pp | -42.1%+21.1pp | -63.2%-6.9pp | -56.3%+25.9pp | |
| Return on assets | -30.1%+5.5pp | -35.6%+3.8pp | -39.5%+18.8pp | -58.3%-4.6pp | -53.7%+24.0pp | |
| Liquidity | ||||||
| Current ratio | 44.3×+0.6× | 43.8×+18.3× | 25.5×+10.4× | 15.1×-11.4× | 26.5×+12.5× | |
| Quick ratio | 44.3×+0.6× | 43.8×+18.3× | 25.5×+10.4× | 15.1×-11.4× | 26.5×+12.5× | |
| Cash ratio | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0×-0.1× | 0.1×+0.1× | |
| Leverage | ||||||
| Interest coverage | -8.7×+2.0× | -10.7×+3.8× | -14.5×+2.0× | -16.5×-1.0× | -15.5×-2.3× | |
| Per Share | ||||||
| Book value per share | $7.70-19.4% | $9.56+17.1% | $8.17+70.4% | $4.79-25.4% | $6.42+63.1% | |
| Valuation | ||||||
| Market capitalization | $2.23B-22.3% | $2.87B-2.4% | $2.94B+219% | $921.58M-7.6% | $997.24M+62.8% | |
| Price / book | 3.5×-0.9× | 4.4×-0.7× | 5.1×+2.2× | 2.9×0.0× | 2.9×-0.3× | |
| Earnings yield | -6.8%-1.4pp | -5.4%+0.4pp | -5.8%+14.9pp | -20.7%-1.8pp | -18.9%+10.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Mineralys Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Mineralys Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.